Prior and concomitant medications
Overall, 26.3% (five patients, [two patients on placebo and three patients on selnoflast]) had at least one immunosuppressive therapy prior to participating in the study (azathioprine: three patients, risankizumab: one patient, and vedolizumab: two patients). One of the patients with prior vedolizumab treatment also had prior anti‐TNF medication (infliximab and golimumab).Twelve patients (63.1%) took mesalazine before and during the study. A total of 18 patients (94.7%) had been vaccinated against COVID‑19 at baseline. After the start of the treatment period, three patients (15.8%) received concomitant medications (beclometasone dipropionate; formoterol fumarate, and nadroparin calcium).